Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

10,935 total articles

Red Cat (RCAT): Buy the Defense Momentum, Prepare for Deep Dilution

Red Cat (RCAT): Buy the Defense Momentum, Prepare for Deep Dilution

Red Cat is riding meaningful defense momentum: contract wins, field-trial validation and sector tailwinds are driving rapid volume and volatility. Fundamentals show a cash cushion per share but large negative free cash flow and persistent losses that make future dilution likely. This trade idea buys the current dip with a tight stop and a mid-term …

Atlassian Is Mispriced on AI - Buy the Re-Rate (Strong Buy)

Atlassian Is Mispriced on AI - Buy the Re-Rate (Strong Buy)

Atlassian's shares trade like a fading SaaS story while the company quietly converts AI investments into higher-value enterprise workloads and cash generation. With a $21.7B market cap, $1.20B in free cash flow and a P/S near 3.7, TEAM offers a high-conviction long with asymmetric risk/reward over the next 180 trading days.

Dollar General Re-Rating Has More Upside — Tactical Long at $121

Dollar General Re-Rating Has More Upside — Tactical Long at $121

Dollar General (DG) is mid-rerating after visible margin improvement, consistent free cash flow and a favorable footprint in price-sensitive markets. Recent Q1 results and guidance lift the fundamental base, valuation is still reasonable (EV/EBITDA ~9.1, P/E ~18), and technicals support a measured long. Entry $121, stop $110, target $140 over a lon…

Buy Summit Therapeutics Ahead of 11/14 PDUFA - Positive Partner Data and a Binary Catalyst to Re-rate

Buy Summit Therapeutics Ahead of 11/14 PDUFA - Positive Partner Data and a Binary Catalyst to Re-rate

Summit Therapeutics (SMMT) is a buy into the 11/14/2026 PDUFA for ivonescimab. The drug’s Phase 3 program showed an overall survival benefit versus chemotherapy and partner data have been described as impressive, giving the stock a clear binary upside if the FDA grants approval. The company’s current market cap is ~$12.1B while the fundamentals sho…

Centene: Cheap FCF and Medicare Tailwinds Make a Risk-Adjusted Long Case

Centene: Cheap FCF and Medicare Tailwinds Make a Risk-Adjusted Long Case

Centene (CNC) looks attractively valued on cash flow metrics despite membership declines. We lay out a long trade targeting $75 with a $61 stop, arguing that Medicare rate increases, cost cutting and a $7.1B FCF cushion give the company time to rebase margins and membership. The plan is for a long-term hold of roughly 180 trading days while watchin…

Advanced Energy: AI Power Demand Should Drive a Mid-Run Upside

Advanced Energy: AI Power Demand Should Drive a Mid-Run Upside

Advanced Energy (AEIS) is benefiting from AI-led data center spending and a cyclical rebound in semiconductor equipment. Recent beats and double-digit top-line growth, combined with management guidance for strong data-center traction, support a mid-term swing trade. Entry at current levels with a disciplined stop preserves reward-to-risk against a …

Embraer: Buy on Delivery Momentum and Valuation Optionality

Embraer: Buy on Delivery Momentum and Valuation Optionality

Embraer looks attractive as a long trade today. A recovery in regional and business jet deliveries, steady defense demand, and an improving supply-chain backdrop give the stock asymmetric upside versus a clear downside buffer. Enter at $22.50, stop $18.00, target $30.00 over a long-term horizon (180 trading days).

Generac: AI Tailwinds Priced for Perfection — A Tactical Short Setup

Generac: AI Tailwinds Priced for Perfection — A Tactical Short Setup

Generac has transformed into a key supplier for AI data centers, driving rapid multiple expansion. The business beats are tangible — commercial growth of 28% and raised guidance — but the market is already paying premium multiples (P/E ~67, EV/EBITDA ~26). This trade idea lays out a mid-term short with precise entry, stop and target, plus catalysts…

Buy the Sentiment Rebound: Netflix Poised for a Recovery Rally

Buy the Sentiment Rebound: Netflix Poised for a Recovery Rally

Netflix ($NFLX) has been punished recently on cautious guidance, but the company still posted record quarterly revenue, strong cash flow and high profitability. Technicals show oversold conditions while catalysts - sports rights, ad-tier expansion, gaming and analyst upgrades - can restore sentiment. We recommend buying at current levels with a mid…

Why IREN’s $4B ARR Justifies a Bold Long — Trade Plan Inside

Why IREN’s $4B ARR Justifies a Bold Long — Trade Plan Inside

IREN is a vertically integrated, renewable-powered data center operator that just crossed an implied $4 billion ARR threshold. With a market cap of roughly $17.98B and an enterprise value of $16.50B, the stock looks positioned for a meaningful re-rating if utilization and long-term contracts continue to scale. This trade idea sets a disciplined ent…

Buy AAR on the Pullback: Play the Connected Aftermarket Recovery

Buy AAR on the Pullback: Play the Connected Aftermarket Recovery

AAR (AIR) is an attractive buy after a sharp intraday pullback. The company is benefiting from accelerating parts sales and MRO demand, has manageable leverage, and still trades well below an aggressive growth-adjusted valuation. Our trade plan buys the dip around $126.62 with a $150 target and an $118 stop, sized for a mid-term horizon as the afte…